Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.
Mar, 16 2026
Apr, 26 2025
Jul, 24 2025
Nov, 22 2025
Dec, 20 2025